These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 36359760)
41. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. Terstappen LW; Nguyen M; Lazarus HM; Medof ME J Leukoc Biol; 1992 Dec; 52(6):652-60. PubMed ID: 1281489 [TBL] [Abstract][Full Text] [Related]
42. Cytokines affect resistance of human renal tumour cells to complement-mediated injury. Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098 [TBL] [Abstract][Full Text] [Related]
43. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301 [No Abstract] [Full Text] [Related]
44. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. Saifuddin M; Parker CJ; Peeples ME; Gorny MK; Zolla-Pazner S; Ghassemi M; Rooney IA; Atkinson JP; Spear GT J Exp Med; 1995 Aug; 182(2):501-9. PubMed ID: 7543140 [TBL] [Abstract][Full Text] [Related]
45. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Clayton A; Harris CL; Court J; Mason MD; Morgan BP Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951 [TBL] [Abstract][Full Text] [Related]
46. Immunomodulatory effects of CD38-targeting antibodies. van de Donk NWCJ Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148 [TBL] [Abstract][Full Text] [Related]
47. Evolving Role of Daratumumab: From Backbencher to Frontline Agent. Jain A; Ramasamy K Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):572-587. PubMed ID: 32331971 [TBL] [Abstract][Full Text] [Related]
48. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study. Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923 [TBL] [Abstract][Full Text] [Related]
49. Integrin and PD-1 Ligand Expression on Circulating Extracellular Vesicles in Systemic Inflammatory Response Syndrome and Sepsis. Kawamoto E; Masui-Ito A; Eguchi A; Soe ZY; Prajuabjinda O; Darkwah S; Park EJ; Imai H; Shimaoka M Shock; 2019 Jul; 52(1):13-22. PubMed ID: 30036273 [TBL] [Abstract][Full Text] [Related]
50. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270 [TBL] [Abstract][Full Text] [Related]
51. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. Schmitz J; Zimmer JP; Kluxen B; Aries S; Bögel M; Gigli I; Schmitz H J Clin Invest; 1995 Sep; 96(3):1520-6. PubMed ID: 7544808 [TBL] [Abstract][Full Text] [Related]
52. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method). Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414 [TBL] [Abstract][Full Text] [Related]
54. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711 [TBL] [Abstract][Full Text] [Related]
55. Daratumumab granted breakthrough drug status. Laubach JP; Tai YT; Richardson PG; Anderson KC Expert Opin Investig Drugs; 2014 Apr; 23(4):445-52. PubMed ID: 24555809 [TBL] [Abstract][Full Text] [Related]
56. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099 [TBL] [Abstract][Full Text] [Related]
57. Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma. Liu J; Xing L; Li J; Wen K; Liu N; Liu Y; Wu G; Wang S; Ogiya D; Song TY; Kurata K; Penailillo J; Morelli E; Wang T; Hong X; Gulla A; Tai YT; Munshi N; Richardson P; Carrasco R; Hideshima T; Anderson KC Nat Commun; 2024 Feb; 15(1):1367. PubMed ID: 38355622 [TBL] [Abstract][Full Text] [Related]